quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:05:00·1d
PRRelease
Fulgent Genetics Inc. logo

Fulgent Selected to Present Rapid Oral Abstract Within the Head and Neck Cancer Track Session at the 2026 ASCO Annual Meeting

FLGT· Fulgent Genetics Inc.
Health Care
Original source

Companies

  • FLGT
    Fulgent Genetics Inc.
    Health Care

Recent analyst ratings

  • Aug 5UpdateUBS$30.00
  • Dec 7UpdateUBS$35.00
  • Dec 8UpdatePiper Sandler$40.00
  • Nov 18UpdateRaymond James$45.00
  • Aug 25UpdateCredit Suisse$65.00
  • Feb 4UpdatePiper Sandler$80.00

Related

  • PR7d
    Fulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026
  • INSIDER23d
    Amendment: SEC Form 4 filed by Hsieh Ming
  • SEC23d
    Amendment: SEC Form SCHEDULE 13D/A filed by Fulgent Genetics Inc.
  • SEC23d
    SEC Form DEFA14A filed by Fulgent Genetics Inc.
  • SEC23d
    SEC Form DEF 14A filed by Fulgent Genetics Inc.
  • SEC37d
    Fulgent Genetics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits
  • PR37d
    Fulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDx
  • INSIDER43d
    SEC Form 4 filed by Chief Executive Officer Hsieh Ming
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022